Molecular profiling of the tumor sample and PDCs using the cancer panel sequencing further confirmed that all three PDCs retained the oncogenic driver mutation, specifically FM-MEL-2 and FM-MEL-3, which exhibited p. Q61K; and FM-MEL-6 exhibited p. Q61R NRAS mutation (Table 1). This evidence concerns the gene NRAS and neoplasm.